Health Canada Temporarily Authorizes Dexcom G6 CGM for Use in Hospitals to Monitor Critically Ill Patients During COVID-19 Pandemic

TORONTO, May 4, 2020 /CNW/ - Health Canada recently announced the Dexcom G6 Continuous Glucose Monitoring (CGM) system has been temporarily authorized for expanded use in hospitals, in an effort to help remotely monitor those who are critically ill during the COVID-19 pandemic. The remote glucose monitoring^* capability of the Dexcom G6 CGM system is expected to reduce caregiver interactions and exposure to COVID-19 in the hospital setting and help to preserve personal protective equipment during the pandemic.

"This has been an incredibly trying time, especially for our front-line health care workers who are putting their own health at risk, day in and day out, to ensure the health and safety of those around them," said Laura Endres, vice president and general manager of Dexcom Canada. "I feel a tremendous sense of gratitude and some relief, knowing that Dexcom CGM systems are not only helping those with diabetes manage their disease while sheltering in place during this pandemic, but also helping our health care workers in hospitals by allowing them to use this technology to remotely monitor their patients, which can reduce their risk of exposure to COVID-19."

The Dexcom G6 CGM System uses a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a smart device or receiver^†, giving patients and now caregivers of critically ill patients, real-time glucose data without the need for a fingerprick.^‡

With customizable alerts and alarms, Dexcom G6 CGM system will remotely alert health care providers treating COVID-19 patients in hospital if a patient is experiencing an urgent hyper- or hypoglycemic event. In addition to providing real-time glucose values, Dexcom CGM systems also display the direction and rate of glucose change, empowering health care providers to take proactive measures to help keep patient glucose levels in target range.

Healthcare facilities interested in using real-time CGM systems to remotely monitor COVID-19 patients should contact [email protected].

About Dexcom, Inc.
Dexcom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, California in the United States, and with operations in Canada, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom simplifies and improves diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.

*Internet connectivity required for data sharing. Following requires the use of the Follow App. Followers should always confirm readings on the Dexcom G6 app or receiver before making treatment decisions.

^†For a list of compatible devices, visit www.dexcom.com/compatibility.  
^‡ If your glucose alerts and readings from Dexcom G6 do not match your symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

SOURCE Dexcom, Inc.

Investor Contact: Steven R. Pacelli, 858.200.0200, Dexcom Strategy and Corporate Development; Media Contact: Alena Atkinson, 705.206.9991, Veritas Communications, [email protected]